Sequenom Shares Rise on Upgrade | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom's shares were up 19 percent in Tuesday afternoon trade after investment bank Lazard Capital Markets upgraded the stock to "buy" from "hold."

Sean Lavin, an analyst for Lazard who covers the firm, issued a research note today upgrading the rating and increasing the price target on Sequenom's shares to $13.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.